References

1. McIntyre P, Amin J, Gidding H, *et al*. Vaccine preventable diseases and vaccination coverage in Australia, 1993–1998. Canberra: Commonwealth Department of Health and Aged Care; 2000. http://www.health.gov.au/internet/wcms/Publishing.nsf/Content/health-pubhlth-publicat-document-cdi-vpd93_98-cnt.htm/$FILE/vpd93_98.pdf (accessed 14 October 2004).

2. McIntyre P, Gidding H, Gilmour R, *et al*. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Communicable Diseases Intelligence 2002;Suppl:1–111. http://www.health.gov.au/internet/wcms/Publishing.nsf/Content/cda-pubs-cdi-2002-cdi26suppl-vpd99_00.htm/$FILE/vpd99_00.pdf (accessed 14 October 2004).

3. Gidding HF, Burgess MA, Kempe AE. A short history of vaccination in Australia [erratum appears in Med J Aust 2001 Mar 5;174(5):260] *Medical Journal of Australia* 2001;174:37–40.

4. Hull BP, McIntyre PB, Heath TC, Sayer GP. Measuring immunisation coverage in Australia. A review of the Australian Childhood Immunisation Register. *Australian Family Physician* 1999;28:55–60.

5. Australian Government Immunise Australia Program. The Seven Point Plan. http://www.health.gov.au:80/pubhlth/strateg/immunis/7point.htm (accessed 19 March 2002).

6. Samaan G, Roche P, Spencer J, National Tuberculosis Advisory Committee for the Communicable Diseases Network Australia. Tuberculosis notifications in Australia, 2002. *Communicable Diseases Intelligence* 2003;27:449–58.

7. Public Health Committee, NHMRC. Surveillance case definitions. Canberra: AGPS; 1994.

8. Blumer C, Roche P, Spencer J, *et al*. Australia's notifiable diseases status, 2001: annual report of the National Notifiable Diseases Surveillance System [erratum appears in *Commun Dis Intell* 2003;27(2):284]. *Communicable Diseases Intelligence* 2003;27:1–78.

9. Yohannes K, Roche P, Blumer C, *et al*. Australia's notifiable diseases status, 2002: annual report of the National Notifiable Diseases Surveillance System. *Communicable Diseases Intelligence* 2004;28:6–68.

10. Australian Institute of Health and Welfare. Australia's health 2004. Cat. No. AUS-44. Canberra: AIHW; 2004.

11. O'Brien ED, Sam GA, Mead C. Methodology for measuring Australia's childhood immunisation coverage. *Communicable Diseases Intelligence* 1998;22:36–7.

12. MacIntyre CR, Ackland MJ, Chandraraj EJ, Pilla JE. Accuracy of ICD-9-CM codes in hospital morbidity data, Victoria: implications for public health research. *Australian & New Zealand Journal of Public Health* 1997;21:477–82.

13. Lister S, McIntyre PB, Burgess MA, O'Brien ED. Immunisation coverage in Australian children: a systematic review 1990–1998. *Communicable Diseases Intelligence* 1999;23:145–70.

14. Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Immunisation coverage in Australia corrected for under-reporting to the Australian Childhood Immunisation Register. *Australian & New Zealand Journal of Public Health* 2003;27:533–8.

15. Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders; 1999.

16. Chin J, editor. Control of communicable diseases manual. 17th ed. Washington DC: American Public Health Association; 2000.

17. Centre for Disease Control Northern Territory. Guidelines for the control of diphtheria in the Northern Territory. Northern Territory Government Department of Health and Community Services; 2004. http://www.nt.gov.au/health/cdc/treatment_protocol/dipthteria.pdf (accessed 14 October 2004).

18. Gidding HF, Burgess MA, Gilbert GL. Diphtheria in Australia, recent trends and future prevention strategies. *Communicable Diseases Intelligence* 2000;24:165–7.

19. de Benoist AC, White JM, Efstratiou A, *et al*. Imported cutaneous diphtheria, United Kingdom. *Emerging Infectious Diseases* 2004;10:511–3.

20. Tharmaphornpilas P, Yoocharoan P, Prempree P, *et al*. Diphtheria in Thailand in the 1990s. *Journal of Infectious Diseases* 2001;184:1035–40.

21. Galazka A. The changing epidemiology of diphtheria in the vaccine era. *Journal of Infectious Diseases* 2000;181 Suppl 1:S2–9.

22. Edmunds WJ, Pebody RG, Aggerback H, *et al*. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network [erratum appears in Epidemiol Infect 2001 Apr;126(2):331]. *Epidemiology & Infection* 2000;125:113–25.

23. Kruszon-Moran DM, McQuillan GM, Chu SY. Tetanus and diphtheria immunity among females in the United States: are recommendations being followed? *American Journal of Obstetrics & Gynecology* 2004;190:1070–6.

24. World Health Organization – Vaccines, Immunization and Biologicals. Diphtheria reported cases. 2004. http://www.who.int/vaccines/globalsummary/timeseries/tsincidencedip.htm (accessed 6 July 2004).

25. Centers for Disease Control and Prevention. Update: diphtheria epidemic–Newly Independent States of the Former Soviet Union, January 1995–March 1996. *MMWR – Morbidity & Mortality Weekly Report* 1996;45:693–7.

26. Koo W, Oley C, Munro R, Tomlinson P. Systemic *Haemophilus influenzae* infection in childhood. *Medical Journal of Australia* 1982;2:77–80.

27. McIntyre PB, Leeder SR, Irwig LM. Invasive *Haemophilus influenzae* type b disease in Sydney children 1985–1987: a population-based study. *Medical Journal of Australia* 1991;154:832–7.

28. Gilbert GL, Clements DA, Broughton SJ. *Haemophilus influenzae* type b infections in Victoria, Australia, 1985 to 1987. *Pediatric Infectious Disease Journal* 1990;9:252–7.

29. McGregor AR, Bell JM, Abdool IM, Collignon PJ. Invasive *Haemophilus influenzae* infection in the Australian Capital Territory region. *Medical Journal of Australia* 1992;156:569–72.

30. Hanna J. The epidemiology and prevention of *Haemophilus influenzae* infections in Australian aboriginal children. *Journal of Paediatrics & Child Health* 1992;28:354–61.

31. O'Grady K-A, Counahan M, Birbilis E, Tallis G, editors. Surveillance of notifiable infectious diseases in Victoria, 2002. Melbourne: Victorian Department of Human Services; 2003.

32. Olowokure B, Hawker J, Blair I, Spencer N. Decrease in effectiveness of routine surveillance of *Haemophilus influenzae* disease after introduction of conjugate vaccine: comparison of routine reporting with active surveillance system. *British Medical Journal* 2000;321:731–2.

33. Communicable Diseases Network Australia. Australian national notifiable diseases list and case definitions. Version 1, 1 January 2004. Canberra: Australian Government Department of Health and Ageing; 2004. http://www.cda.gov.au/surveil/nndss/dislist.htm#casedefs (accessed 13 July 2004).

34. Hanna JN. Impact of *Haemophilus influenzae* type b (Hib) vaccination on Hib meningitis in children in Far North Queensland, 1989 to 2003. *Communicable Diseases Intelligence* 2004;28:255–7.

35. Heath PT, Booy R, Azzopardi HJ, *et al*. Non-type b *Haemophilus influenzae* disease: clinical and epidemiologic characteristics in the *Haemophilus influenzae* type b vaccine era. *Pediatric Infectious Disease Journal* 2001;20:300–5.

36. Mayo-Smith MF, Spinale JW, Donskey CJ, *et al*. Acute epiglottitis: an 18-year experience in Rhode Island. *Chest* 1995;108:1640–7.

37. Wong EY, Berkowitz RG. Acute epiglottitis in adults: the Royal Melbourne Hospital experience. *Australian and New Zealand Journal of Surgery* 2001;71:740–3.

38. Frantz TD, Rasgon BM, Quesenberry CP, Jr. Acute epiglottitis in adults: analysis of 129 cases. *Journal of the American Medical Association* 1994;272:1358–60.

39. Wood N, Menzies R, McIntyre P. Epiglottitis in Sydney before and after the introduction of vaccination against *Haemophilus influenzae* type b (Hib) disease [poster presentation]. Canberra: Royal Australasian College of Physicians Annual Scientific Meeting, 17–19 May 2004.

40. Tanner K, Fitzsimmons G, Carrol ED, Flood TJ, Clark JE. *Haemophilus influenzae* type b epiglottitis as a cause of acute upper airways obstruction in children. *British Medical Journal* 2002;325:1099–100.

41. Garner D, Weston V. Effectiveness of vaccination for *Haemophilus influenzae* type b. *Lancet* 2003;361:395–6.

42. McVernon J, Moxon R, Heath P, Ramsay M, Slack M. *Haemophilus influenzae* type b epiglottitis: article gives timely lesson. *British Medical Journal* 2003;326:284.

43. Conaty S, Bird P, Bell G, *et al*. Hepatitis A in New South Wales, Australia from consumption of oysters: the first reported outbreak. *Epidemiology & Infection* 2000;124:121–30.

44. Ferson MJ, Young LC, Stokes ML. Changing epidemiology of hepatitis A in the 1990s in Sydney, Australia. *Epidemiology & Infection* 1998;121:631–6.

45. Hanna JN, Warnock TH, Shepherd RW, Selvey LA. Fulminant hepatitis A in indigenous children in north Queensland. *Medical Journal of Australia* 2000;172:19–21.

46. Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA. Hepatitis A epidemiology in Australia: national seroprevalence and notifications. *Medical Journal of Australia* 2001;174:338–41.

47. Gilroy NM, Tribe IG, Passaris I, Hall R, Beers MY. Hepatitis A in injecting drug users: a national problem. *Medical Journal of Australia* 2000;172:142–3.

48. MacIntyre CR, Burgess MA, Hull B, McIntyre PB. Hepatitis A vaccination options for Australia. *Journal of Paediatrics & Child Health* 2003;39:83–7.

49. National Health and Medical Research Council. *The Australian immunisation handbook*. 8th ed. Canberra: Australian Government Publishing Service: 2003. Referenced version available at http://www1.health.gov.au/immhandbook/ (accessed 14 October 2004).

50. Menzies R, McIntyre P, Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. *Communicable Diseases Intelligence* 2004;28:127–59.

51. D'Argenio P, Adamo B, Cirrincione R, Gallo G. The role of vaccine in controlling hepatitis A epidemics. *Vaccine* 2003;21:2246–9.

52. Hanna JN, Hills SL, Humphreys JL. The impact of hepatitis A vaccination of Indigenous children on the incidence of hepatitis A in North Queensland. Canberra: Communicable Diseases Control Conference, 31 March–1 April 2003.

53. Jenson HB. The changing picture of hepatitis A in the United States. *Current Opinion in Pediatrics* 2004;16:89–93.

54. Kaldor JM, Plant AJ, Thompson SC, Longbottom H, Rowbottom J. The incidence of hepatitis B infection in Australia: an epidemiological review. *Medical Journal of Australia* 1996;165:322–6.

55. Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: chronic viral hepatitis. *British Medical Journal* 2001;322:219–21.

56. O'Sullivan BG, Gidding HF, Law M, *et al*. Estimates of chronic hepatitis B virus infection in Australia, 2000. *Australian & New Zealand Journal of Public Health* 2004;28:212–6.

57. Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. *Vaccine* 2000;18 Suppl 1:S35–8.

58. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978–1997: increasing incidence and mortality. *Medical Journal of Australia* 2000;173:403–5.

59. Williams A. Reduction in the hepatitis B related burden of disease - measuring the success of universal immunisation programs. *Communicable Diseases Intelligence* 2002;26:458–60.

60. Skinner R, Nolan T. Adolescent hepatitis B immunisation – should it be the law? *Australian & New Zealand Journal of Public Health* 2001;25:230–3.

61. Condon JR, Barnes T, Cunningham J, Armstrong BK. Long-term trends in cancer mortality for Indigenous Australians in the Northern Territory. *Medical Journal of Australia* 2004;180:504–7.

62. Roche P, Spencer J, Hampson A. Annual report of the National Influenza Surveillance Scheme, 2001. *Communicable Diseases Intelligence* 2002;26:204–13.

63. Lister S, McIntyre PB, Menzies R. The epidemiology of respiratory syncytial virus infections in NSW children, 1992–1997. *New South Wales Public Health Bulletin* 2000;11:119–23.

64. Druce J, Tran T, Kelly H, *et al.* Laboratory diagnosis and surveillance by PCR of human respiratory viruses in Melbourne, Australia 2002–3. *Journal of Medical Virology* 2004. In press.

65. Turner J, Tran T, Birch C, Kelly H. Higher than normal seasonal influenza activity in Victoria, 2003. *Communicable Diseases Intelligence* 2004;28:175–80.

66. Nichol KL, Nordin J, Mullooly J, *et al*. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. *New England Journal of Medicine* 2003;348:1322–32.

67. Izurieta HS, Thompson WW, Kramarz P, *et al*. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *New England Journal of Medicine* 2000;342:232–9.

68. Armstrong B, Mangtani P, Fletcher A, *et al*. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. *British Medical Journal* 2004;329:660. http://bmj.com/cgi/content/full/329/7467/660 (accessed 18 September 2004).

69. Thompson WW, Shay DK, Weintraub E, *et al*. Mortality associated with influenza and respiratory syncytial virus in the United States. *Journal of the American Medical Association* 2003;289:179–86.

70. Simonsen L, Clarke MJ, Schonberger LB, *et al*. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. *Journal of Infectious Diseases* 1998;178:53–60.

71. Australian Institute of Health and Welfare. 2002 Influenza vaccine survey: summary results. AIHW cat. no. PHE 46. Canberra: Australian Institute of Health and Welfare; 2003. http://www.aihw.gov.au/publications/phe/ivs02sr/ivs02sr.pdf (accessed 14 October 2004).

72. Australian Institute of Health and Welfare. 2003 Influenza vaccine survey: summary results. AIHW cat. no. PHE 51. Canberra: Australian Institute of Health and Welfare & Australian Government Department of Health and Ageing; 2004. http://www.aihw.gov.au/publications/phe/ivs03sr/ivs03sr.pdf (accessed 14 October 2004).

73. Carman WF, Elder AG, Wallace LA, *et al*. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. *Lancet* 2000;355:93–7.

74. Centers for Disease Control and Prevention. Update: influenza activity–United States, 2003–04 season. *MMWR Morbidity & Mortality Weekly Report* 2004;53:284–7.

75. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. *New England Journal of Medicine* 2000;342:225–31.

76. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule – United States, January–June 2004. *MMWR Morbidity & Mortality Weekly Report* 2004;53:Q1–4.

77. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for influenza immunization of children. *Pediatrics* 2004;113:1441–7.

78. Kappagoda C, Isaacs D, Mellis C, *et al*. Critical influenza virus infection. *Journal of Paediatrics & Child Health* 2000;36:318–21.

79. McIntosh K, Lieu T. Is it time to give influenza vaccine to healthy infants? *New England Journal of Medicine* 2000;342:275–6.

80. Yohannes K, Roche P, Spencer J, Hampson A. Annual report of the National Influenza Surveillance Scheme, 2002. *Communicable Diseases Intelligence* 2003;27:162–72.

81. Avian influenza: frequently asked questions. *Weekly Epidemiological Record* 2004;79:77–83.

82. Webby RJ, Webster RG. Are we ready for pandemic influenza? *Science* 2003;302:1519–22.

83. Fedson DS. Vaccination for pandemic influenza: a six point agenda for interpandemic years. *Pediatric Infectious Disease Journal* 2004;23:S74–7.

84. World Health Organization Communicable Disease Surveillance & Response (CSR). Guidelines for the use of seasonal influenza vaccine in humans at risk of H5N1 infection; 2004. http://www.who.int/csr/disease/avian_influenza/guidelines/seasonal_vaccine/en/ (accessed 25 August 2004).

85. Davidson N, Andrews R, Riddell M, *et al*. A measles outbreak among young adults in Victoria, February 2001. *Communicable Diseases Intelligence* 2002;26:273–8.

86. Andrews R, O'Grady K-A, Tallis G, editors. Surveillance of notifiable infectious diseases in Victoria 2001. Melbourne: Communicable Diseases Section, Rural & Regional Health & Aged Care Services, Victorian Department of Human Services; 2002.

87. Hanna JN, Symons DJ, Lyon MJ. A measles outbreak in the Whitsundays, Queensland: the shape of things to come? *Communicable Diseases Intelligence* 2002;26:589–92.

88 Centers for Disease Control and Prevention. Progress toward measles elimination – region of the Americas, 2002–2003. *MMWR Morbidity & Mortality Weekly Report* 2004;53:304–6.

89. Peltola H, Davidkin I, Paunio M, *et al*. Mumps and rubella eliminated from Finland. *Journal of the American Medical Association* 2000;284:2643–7.

90. World Health Organization, United Nations Children's Fund. Measles mortality reduction and regional elimination strategic plan 2001–2005. WHO/V&B/01.13 Rev.1. Geneva: World Health Organization; 2001. http://www.who.int/vaccines-documents/DocsPDF01/www573.pdf (accessed 14 October 2004).

91. McIntyre PB, Gidding HF, Gilbert GL. Measles in an era of measles control. *Medical Journal of Australia* 2000;172:103–4.

92. Lambert SB, Kelly HA, Andrews RM, *et al*. Enhanced measles surveillance during an interepidemic period in Victoria. *Medical Journal of Australia* 2000;172:114–8.

93. Gidding HF. The impact of Australia's measles control programme over the past decade. *Epidemiology & Infection* 2004. In press.

94. Turnbull FM, Burgess MA, McIntyre PB, *et al*. The Australian Measles Control Campaign, 1998. *Bulletin of the World Health Organization* 2001;79:882–8.

95. Campbell M. Young adult measles vaccination. *Communicable Diseases Intelligence* 2000;24:241–2.

96. Gidding HF, Young M, Pugh R, Burgess M. Rubella in Australia: can we explain two recent cases of congenital rubella syndrome? *Communicable Diseases Intelligence* 2003;27:537–40.

97. World Health Organization, Regional Office for the Western Pacific Expanded Programme on Immunization. *Measles Bulletin* 2004;1:1–4. http://www.wpro.who.int/pdf/EPI/Measles%20Bulletin%201.pdf (accessed 14 October 2004).

98. Chibo D, Riddell M, Catton M, *et al*. Studies of measles viruses circulating in Australia between 1999 and 2001 reveals a new genotype. *Virus Research* 2003;91:213–21.

99. Roche P, Spencer J, Merianos A. Meningococcal disease [erratum appears in Commun Dis Intell 2001 Nov;25(4):280]. *Communicable Diseases Intelligence* 2001;25:126–9.

100. Ward J, Hanna JN, Bates JR, Selvey LA. Enhanced surveillance for meningococcal disease in Queensland in 1999. *Communicable Diseases Intelligence* 2000;24:332–5.

101. Pugh RE, Smith H, Young M. Surveillance of invasive meningococcal disease in Queensland, 2002. *Communicable Diseases Intelligence* 2003;27:342–51.

102. Hogan D, McAnulty J. Meningococcal disease in New South Wales, 1991–2002. *New South Wales Public Health Bulletin* 2004;15:39–43.

103. Jelfs J, Munro R. Epidemiology of meningococcal disease in Australia. *Journal of Paediatrics & Child Health* 2001;37:S3–6.

104. Tapsall J. Meningococcal vaccines: advances but new questions? *Journal of Paediatrics & Child Health* 2001;37: S1–2.

105. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. *Vaccine* 2001;20 Suppl 1:S58–67.

106. Australian Meningococcal Surveillance Program. Annual report of the Australian Meningococcal Surveillance Programme, 2000. *Communicable Diseases Intelligence* 2001;25:113–21.

107. Australian Meningococcal Surveillance Program. Annual report of the Australian Meningococcal Surveillance Programme, 2002. *Communicable Diseases Intelligence* 2003;27:196–208.

108. Australian Meningococcal Surveillance Program. Annual report of the Australian Meningococcal Surveillance Programme, 2001. *Communicable Diseases Intelligence* 2002;26:407–18.

109. Robinson P, Griffith J, Taylor K, *et al*. Laboratory enhanced surveillance for meningococcal disease in Victoria. *Journal of Paediatrics & Child Health* 2001;37:S7–12.

110. Mooney JD, Christie P, Robertson C, Clarke SC. The impact of meningococcal serogroup C conjugate vaccine in Scotland. *Clinical Infectious Diseases* 2004;39:349–56.

111. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. *Lancet* 2004;364:365–7.

112. Cohen NJ. Introduction of the National Meningococcal C Vaccination Program. *Communicable Diseases Intelligence* 2003;27:161–2.

113. Groseclose SL, Brathwaite WS, Hall PA, *et al*. Summary of notifiable diseases–United States, 2002. *MMWR Morbidity & Mortality Weekly Report* 2004;51:1–84.

114. Guy RJ, Andrews RM, Kelly HA, *et al*. Mumps and rubella: a year of enhanced surveillance and laboratory testing. *Epidemiology & Infection* 2004;132:391–8.

115. Guy RJ, Andrews RM, Robinson PM, Lambert SB. Mumps and rubella surveillance in Victoria, 1993 to 2000. *Communicable Diseases Intelligence* 2003;27:94–9.

116. Guy R, Leydon J, Andrews R, Lambert S. The mumps outbreak that wasn't. *Australian & New Zealand Journal of Public Health* 2002;26:180–1.

117. Communicable Diseases Network Australia. Australian national notifiable diseases list and case definitions. Version 1, 1 January 2004. Canberra: Australian Government Department of Health and Ageing; 2004. http://www.cda.gov.au/surveil/nndss/dislist.htm#casedefs (accessed 29 June 2004).

118. Torvaldsen S, McIntyre P. Do variations in pertussis notifications reflect incidence or surveillance practices? A comparison of infant notification rates and hospitalisation data in NSW. *New South Wales Public Health Bulletin* 2003;14:81–4.

119. Bonacruz-Kazzi G, McIntyre P, Hanlon M, Menzies R. Diagnostic testing and discharge coding for whooping cough in a children's hospital. *Journal of Paediatrics & Child Health* 2003;39:586–90.

120. Elliott E, McIntyre P, Ridley G, *et al*. National study of infants hospitalized with pertussis in the acellular vaccine era. *Pediatric Infectious Disease Journal* 2004;23:246–52.

121. Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. *Pediatric Infectious Disease Journal* 2003;22:956–9.

122. Brotherton J, McAnulty J. A pertussis epidemic in NSW: how epidemiology reflects vaccination policy. *New South Wales Public Health Bulletin* 2003;14:77–81.

123. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. *Pediatric Infectious Disease Journal* 2003;22:22–7.

124. Guris D, Strebel PM, Bardenheier B, *et al*. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. *Clinical Infectious Diseases* 1999;28:1230–7.

125. Turnbull FM, Heath TC, Jalaludin BB, Burgess MA, Ramalho AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. *Vaccine* 2000;19:628–36.

126. Salmaso S, Mastrantonio P, Tozzi AE, *et al*. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. *Pediatrics* 2001;108:E81.

127. Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. *Medical Journal of Australia* 2003;179:191–4.

128. Roche P, Krause V, Enhanced Pneumococcal Surveillance Group of the Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2001. *Communicable Diseases Intelligence* 2002;26:505–19.

129. Roche P, Krause V, Andrews R, *et al*. Invasive pneumococcal disease in Australia, 2002. *Communicable Diseases Intelligence* 2003;27:466–77.

130. Andrews RM, Lester RA. Improving pneumococcal vaccination coverage among older people in Victoria. *Medical Journal of Australia* 2000;173 Suppl:S45–7.

131. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders; 1999.

132. Krause VL, Reid SJ, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994–1998. *Medical Journal of Australia* 2000;173 Suppl:S27–31.

133. The Vaccine Impact Surveillance Network – Invasive Pneumococcal Study Group. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? *Medical Journal of Australia* 2000;173 Suppl: S36–40.

134. Hanna JN, Young DM, Brookes DL, Dostie BG, Murphy DM. The initial coverage and impact of the pneumococcal and influenza vaccination program for at-risk indigenous adults in Far North Queensland. *Australian & New Zealand Journal of Public Health* 2001;25:543–6.

135. Benin AL, O'Brien KL, Watt JP, *et al*. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. *Journal of Infectious Diseases* 2003;188:81–9.

136. Department of Health and Aged Care. National documentation for certification of poliomyelitis eradication in Australia. Canberra: Ausinfo; 2000.

137. Sullivan AA, Boyle RS, Whitby RM. Vaccine-associated paralytic poliomyelitis. *Medical Journal of Australia* 1995;163:423–4.

138. Thorley BR, Brussen KA, Stambos V, Yuen LK, Kelly HA. Annual report of the Australian National Poliovirus Reference Laboratory and summary of acute flaccid paralysis surveillance, 2001. *Communicable Diseases Intelligence* 2002;26:419–27.

139. Thorley BR, Brussen KA, Stambos V, Kelly H. Annual report of the Australian National Poliovirus Reference Laboratory, 2002. *Communicable Diseases Intelligence* 2003;27:352–6.

140. World Health Organization. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. *Weekly Epidemiological Record* 2003;78:241–50.

141. World Health Organization Press Release WHO/71 (29 October 2000). Major milestone reached in global polio eradication: Western Pacific Region is certified polio-free. *Communicable Diseases Intelligence* 2000;24:304.

142. Hovi T, Wassilak S. The importance of maintaining high coverage polio vaccination beyond global eradication of wild type poliomyelitis. *Eurosurveillance Weekly* 2004;8. http://www.eurosurveillance.org/ew/2004/040122.asp (accessed 21 July 2004).

143. Sullivan EM, Burgess MA, Forrest JM. The epidemiology of rubella and congenital rubella in Australia, 1992 to 1997. *Communicable Diseases Intelligence* 1999;23:209–14.

144. Elliot E, Ridley G, Morris A, Redmond D, Williams G, editors. Australian Paediatric Surveillance Unit Eighth Annual Report 2000. Sydney: APSU; 2001.

145. Elliot E, Ridley G, Rose D, editors. Australian Paediatric Surveillance Unit Ninth Annual Report 2001. Sydney: APSU; 2002.

146. Castillo-Solorzano C, Carrasco P, Tambini G, *et al*. New horizons in the control of rubella and prevention of congenital rubella syndrome in the Americas. *Journal of Infectious Diseases* 2003;187 Suppl 1:S146–52.

147. Gilbert GL, Escott RG, Gidding HF, *et al.* Impact of the Australian Measles Control Campaign on immunity to measles and rubella. *Epidemiology & Infection* 2001;127:297–303.

148. Kelly H, Worth L, Karapanagiotidis T, Riddell M. Interruption of rubella virus transmission in Australia may require vaccination of adult males: evidence from a Victorian sero-survey. *Communicable Diseases Intelligence* 2004;28:69–73.

149. Forrest JM, Burgess M, Donovan T. A resurgence of congenital rubella in Australia? *Communicable Diseases Intelligence* 2003;27:533–5.

150. Centers for Disease Control and Prevention. Global Disease Elimination and Eradication as Public Health Strategies. Proceedings of a conference. Atlanta, Georgia, USA. 23–25 February 1998. *MMWR - Morbidity & Mortality Weekly Report* 1999;48 Suppl:1–208.

151. Turnbull F, Baker M, Tsang B, Jarman J. Epidemiology of tetanus in New Zealand reinforces value of vaccination. *New Zealand Public Health Report* 2001;8:57–60.

152. Gidding H, Backhouse J, Gilbert GL., MacIntyre CR, Burgess MA. The first national serosurvey of vaccine preventable diseases – an overview. Abstract presented at *A boost for immunisation*, 8th national Public Health Association of Australia immunisation conference, Melbourne, 16–17 May 2002: 26.

153. Management of tetanus prone wounds: tetanus immunoglobulin may be necessary. *Tropical Public Health Unit for North Queensland Communicable Disease Control newsletter* 2002;No. 40, August:2.

154. Government of South Australia – Department of Human Services Communicable Disease Control Branch. Communicable disease surveillance report: notifications with disease onset dates between 1 October to 31 December 2001 inclusive. *CDC Bulletin* 2002;11:4.

155. Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance – United States, 1998–2000. *MMWR – Morbidity & Mortality Weekly Report Surveillance Summaries* 2003;52:1–8.

156. Rushdy AA, White JM, Ramsay ME, Crowcroft NS. Tetanus in England and Wales, 1984–2000. *Epidemiology & Infection* 2003;130:71–7.

157. Health Protection Agency. Ongoing national outbreak of tetanus in injecting drug users. *Communicable Disease Report CDR Weekly* 2004;14:2–4. http://www.hpa.org.uk/cdr/PDFfiles/2004/cdr0904.pdf (accessed 8 July 2004).

158. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. *Pediatric Infectious Disease* 1984;3:505–9.

159. Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. *Epidemiology & Infection* 2003;131:1085–9.

160. Guess HA, Broughton DD, Melton LJ, III, Kurland LT. Population-based studies of varicella complications. *Pediatrics* 1986;78:723–7.

161. Brody MB, Moyer D. Varicella-zoster virus infection: the complex prevention-treatment picture. *Postgraduate Medicine* 1997;102:187–90.

162. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. *European Journal of Pain* 1999;3:335–42.

163. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. *Journal of Infectious Diseases* 2000;181:1897–905.

164. Guess HA, Broughton DD, Melton LJ, III, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. *Pediatrics* 1985;76:512–7.

165. Gershon AA. Prevention and treatment of VZV infections in patients with HIV. *Herpes* 2001;8:32–6.

166. Forrest J, Mego S, Burgess M. Congenital and neonatal varicella in Australia. *Journal of Paediatrics & Child Health* 2000;36:108–13.

167. MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. *Epidemiology & Infection* 2003;131:675–82.

168. Seward JF, Watson BM, Peterson CL, *et al*. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. *Journal of the American Medical Association* 2002;287:606–11.

169. Hope Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). *Lancet* 1952;2:549–54.

170. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. *Epidemiology & Infection* 2000;125:651–69.

171. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. *Lancet* 2002;360:678–82.

172. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. *Vaccine* 2002;20:2500–7.

173. Childhood immunisation coverage. *Communicable Diseases Intelligence* 1998;22:233.

174. Childhood immunisation coverage. *Communicable Diseases Intelligence* 2002;26:491–3.

175. Lawrence GL, Hull BP, MacIntyre CR, McIntyre PB. Reasons for incomplete immunisation among Australian children: a national survey of parents. *Australian Family Physician* 2004;33:568–71.

176. Taylor A, Wilson D, Dal Grande E, Gill T. National influenza survey: a population survey of vaccination uptake in Australia - October 2000. Adelaide: South Australian Department of Human Services, 2000. http://www.dhs.sa.gov.au/pehs.CPSE/flu-vaccination-2000.pdf (accessed 8 April 2002).

177. Wilson K, Mills E, Ross C, McGowan J, Jadad A. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. *Archives of Pediatrics & Adolescent Medicine* 2003;157:628–34.

178. Department of Health (UK). NHS Immunisation statistics, England: 2003–04. Bulletin No. 16, 2004. http://www.publications.doh.gov.uk/public/sb0416.pdf (accessed 30 September 2004).

179. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating *Haemophilus influenzae* type b vaccine effectiveness in England and Wales by use of the screening method. *Journal of Infectious Diseases* 2003;188:481–5.

180. McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in *Haemophilus influenzae* type b infections in adults in England and Wales: surveillance study. *British Medical Journal* 2004;329:655–8.

181. Baker M, Taylor P, Wilson E, Jones N, Short P. A case of diphtheria in Auckland – implications for disease control. *New Zealand Public Health Report* 1998;5:73–6.

182. Roche P, Krause V, Enhanced Pneumococcal Surveillance Group of the Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2001. *Communicable Diseases Intelligence* 2002;26:505–19.

183. Roche P, Krause V, Andrews R, *et al.* Invasive pneumococcal disease in Australia, 2002. *Communicable Diseases Intelligence* 2003;27:466–77.

184. Whitney CG, Farley MM, Hadler J, *et al*. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *New England Journal of Medicine* 2003;348:1737–46.

185. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. *Journal of Paediatrics & Child Health* 2001;37:S20–7.

186. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. *Journal of Paediatrics & Child Health* 2001;37:S13–9.

187. New Zealand Ministry of Health, Institute of Environmental Science and Research Ltd. Monthly Surveillance Report: May 2003–May 2004. http://www.surv.esr.cri.nz/surveillance/monthly_surveillance.php (accessed 29 July 2004).

188. Health Canada. Population and Public Health Branch. Notifiable Diseases On-Line 2004. http://dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/c_dis_e.html (accessed 29 July 2004).

189. Health Protection Agency. Infectious Diseases. Epidemiological data. Notifications by region. 2004. http://www.hpa.org.uk/infections/default.htm (accessed 29 July 2004).

190. Lawrence GL, MacIntyre CR, Hull BP, McIntyre PB. Effectiveness of the linkage of childcare and maternity payments to childhood immunisation. *Vaccine* 2004;22:2345–50.

191. Australian Government Department of Health and Ageing. Review of the General Practice Immunisation Incentives (GPII) scheme. Canberra: Australian Government Department of Health and Ageing; 2004. http://www.health.gov.au/pubhlth/strateg/immunis/gpii_review.pdf (accessed 30 September 2004).